FOXO Technologies Inc. reported persistent capital access issues in its most recent quarterly filing, including FINRA’s denial of a proposed reverse stock split essential for raising additional financing. Despite these constraints, FOXO continues to develop its integrated business model comprising rural healthcare delivery, behavioral health services, life science biospecimen sourcing, and early-stage epigenetic labs. The company’s ownership of a Critical Access Hospital and established biospecimen logistics anchors a unique but capital-intensive niche in underserved markets. Major risks center on liquidity shortfalls, regulatory complexities, and integration execution risks. Upcoming milestones include resolution of the reverse split appeal and new capital raises critical for operation funding.